CALQUENCE®▼ (acalabrutinib)

CALQUENCE® (acalabrutinib) is een remmer van het Bruton Tyrosine Kinase (BTK)
voor de behandeling van chronische lymfatische leukemie (CLL).1

Team

Uw contactpersonen

 

 

Margot Peeters
Hospital Representative
Hematology
& Gastrointestinal Oncology Flanders

Joke Van Den Berge
Hospital Representative
Hematology
& Gastrointestinal Oncology Flanders

Stéphane Lemaire
Hospital Representative
Hematology
& Gastrointestinal Oncology 
Wallonia & Luxembourg

Véronique Petit
Hospital Representative
Hematology
& Gastrointestinal Oncology Wallonia

Evelien Van Schoor
Medical Advisor
Hematology

 

 

 

Het bredere team Hematology

 

 

Tom Ghysels
Business Unit Director
Oncology & Hematology

Joeri Van Op den Bosch
Franchise Lead 
Hematology
& Gastrointestinal Oncology

Thierry Marysael
Medical Affairs Lead
Hematolog/Breast
& ovarian cancer

Maureen Van Well
Government Affairs &
Market Access Lead
Oncology

Tine Cuppens
Medical Affairs Manager
Hematology

Zakaria Bouzaiane
Brand Manager
Hematology
& Gastrointestinal Oncology

Marieke Siemons
First Line Sales Manager
Hematology
& Gastrointestinal Oncology